Advances in Therapy

, Volume 24, Issue 6, pp 1260–1270 | Cite as

Medium-term effects of bisoprolol administration on renal hemodynamics and function in mild to moderate essential hypertension

  • Salvatore Paterna
  • Gaspare Parrinello
  • Pietro Di Pasquale
  • Daniele Torres
  • Gabriella La Rocca
  • Roberta Antona
  • Laura Vernuccio
  • Ersilia Fornaciari
  • Antonina Tarantino
  • Ercole Piccione
  • Sergio Fasullo
  • Giuseppe Licata


Arterial hypertension is a significant cause of end-stage renal failure; effective treatment of hypertensive patients reduces the rate of progression of this disorder. β-Blockers, particularly nonselective agents, are associated with deterioration of renal function in patients with chronic renal failure. Previous studies on the interaction of the β1-selective adrenergic antagonist bisoprolol with kidney function have been performed only acutely and over the short term. This study was designed to evaluate the antihypertensive efficacy and effects on renal hemodynamics and function of bisoprolol during medium-term (6 mo) treatment of patients with mild to moderate essential hypertension. After a 2-wk run-in period on placebo, 87 consecutive hypertensive patients (46 men, 41 women) according to ESH-ESC (European Society of Hypertension/European Society of Cardiology) guidelines, aged from 27 to 64 y (mean age, 50±11 y), without renal or cardiovascular disease, were enrolled and assigned to treatment with bisoprolol 5 mg once daily for 6 mo. At recruitment and at 6 mo after treatment, renal function was assessed and renal hemodynamics evaluated in all patients through radioisotope studies. The mediumterm effects of bisoprolol included a significant reduction in blood pressure and heart rate (P< .001) without significant adverse drug reactions. Moreover, bisoprolol produced no alteration in renal function or hemodynamics, or in cardiac output. Data presented here indicate that bisoprolol 5 mg given once daily to treat patients with mild to moderate essential hypertension is effective and safe for treatment and for preservation of renal performance when given on a medium-term basis.


bisoprolol essential hypertension renal hemodynamics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age.Kidney Int. 1984;26:861–868.CrossRefPubMedGoogle Scholar
  2. 2.
    London GM, Safar ME, Sassard JE, Levenson JA, Simon AC. Renal and systemic haemodynamics in sustained essential hypertension.Hypertension. 1984;6:743–754.PubMedGoogle Scholar
  3. 3.
    Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis.Kidney Int Suppl. 2005;99:S52-S56.CrossRefPubMedGoogle Scholar
  4. 4.
    Brenner BM. Nephron adaptation to renal injury or ablation.Am J Physiol. 1985;249:F324-F327.PubMedGoogle Scholar
  5. 5.
    Dworkin LD, Feiner HD, Randazzo J. Glomerular injury in uninephrectomized spontaneously hypertensive rats: a consequence of glomerular capillary hypertension.J Clin Invest. 1986;77: 797–809.CrossRefPubMedGoogle Scholar
  6. 6.
    Ljungman S, Wikstrand J, Hartford M, Aurell M, Lindstedt G, Berglund G. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.Am J Hypertens. 1993;6:554–563.PubMedGoogle Scholar
  7. 7.
    Cruickshank JM. Are we understanding beta-blockers?Int J Cardiol. 2007;120:10–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Waal-Manning HJ. Atenolol and three nonselective beta-blockers in hypertension.Pharmacol Ther. 1979;25:8–18.Google Scholar
  9. 9.
    Manning HJ, Bolli P. Atenolol versus placebo in mild hypertension: renal metabolic and stress antipressor effects.Br J Clin Pharmacol. 1980;9:553–560.Google Scholar
  10. 10.
    Warren DJ, Swainson CP, Wright N. Deterioration in renal function after beta-blockade in patients with chronic renal failure and hypertension.Br Med J. 1974;2:193–194.CrossRefPubMedGoogle Scholar
  11. 11.
    Snell A, Wallace M. Beta blockade in the presence of renal disease and hypertension.Br Med J. 1974;2:672.CrossRefPubMedGoogle Scholar
  12. 12.
    Swainson CP, Winney RJ. Effect of beta-blockade in chronic renal failure.Br Med J. 1976;1:459.CrossRefPubMedGoogle Scholar
  13. 13.
    Johns TE, Lopez LM. Bisoprolol: is this just another beta-blocker for hypertension or angina?Ann Pharmacother. 1995;29:403–414.PubMedGoogle Scholar
  14. 14.
    Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).Cardiovasc Drugs Ther. 2003;17:257–263.CrossRefPubMedGoogle Scholar
  15. 15.
    ESH/ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.J Hypertens. 2003, 21: 1011–1053.CrossRefGoogle Scholar
  16. 16.
    Schlegel JU, Haway SA. Individual renal plasma flow determination in 2 minutes.J Urol. 1976; 111:282–288.Google Scholar
  17. 17.
    Gates GE. Glomerular filtration rate: estimation from fractional renal accumulation of 99m-Tc-DTPA.Am J Radiol. 1981;138:565–570.Google Scholar
  18. 18.
    Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantification of left ventricle by two dimensional echocardiography.J Am Soc Echocardiogr. 1989;2:358–367.PubMedGoogle Scholar
  19. 19.
    Bakris GL, Hart P, Ritz E. Beta-blockers in the management of chronic kidney disease.Kidney Int. 2006;70:1905–1913.PubMedGoogle Scholar
  20. 20.
    Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio J. Does an adequate control of blood pressure protect the kidney in essential hypertension?J Hypertens. 1990;8:525–531.CrossRefPubMedGoogle Scholar
  21. 21.
    Parving HH, Andersen AR, Smith UM, Home L, Mathiesen ES, Svendsen PA. Effect of antihypertensive treatment on kidney function and diabetic nephropathy.BMJ. 1987;294:1443–1447.CrossRefPubMedGoogle Scholar
  22. 22.
    Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors.Br J Pharmacol. 2005;144:317–322.CrossRefPubMedGoogle Scholar
  23. 23.
    Oral I, Vareka I, Marek D. The effect of a single dose of bisoprolol on changes in blood pressure and hemodynamic indicators in patients with mild hypertension.Vnitr Lek. 1992;38:980–985.PubMedGoogle Scholar
  24. 24.
    Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure.Kidney Int. 1989;35:670–674.CrossRefPubMedGoogle Scholar
  25. 25.
    Scaglione R, Ganguzza A, Corrao S, et al. Effect of cilazapril on renal haemodynamics and function in hypertensive patients: a randomised controlled study versus hydrochlorothiazide.Blood Press. 1995;4:363–368.CrossRefPubMedGoogle Scholar
  26. 26.
    Scaglione R, Indovina A, Parrinello G, et al. Antihypertensive efficacy and effects of nitrendipine on cardiac and renal hemodynamics in mild to moderate hypertensive patients: randomized controlled trial versus hydrochlorothiazide.Cardiovasc Drugs Ther. 1992;6:141–146.CrossRefPubMedGoogle Scholar
  27. 27.
    Paterna S, Parrinello G, Scaglione R, et al. Effect of long-term losartan administration on renal haemodynamics and function in hypertensive patients.Cardiovasc Drugs Ther. 2000;14:529–532.CrossRefPubMedGoogle Scholar
  28. 28.
    Licata G, Scaglione R, Guillet C, et al. Double-blind controlled study of rilmenidine versus hydrochlorothiazide in mild hypertension: clinical and renal haemodynamic evaluation.J Hum Hypertens. 1992;6:140–146.Google Scholar
  29. 29.
    Licata G, Scaglione R, Ganguzza A, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients: a randomized controlled study versus placebo.Eur J Clin Pharmacol. 1993;45:307–311.CrossRefPubMedGoogle Scholar
  30. 30.
    Uehara Y, Takada S, Hirawa N, et al. Vasoconstrictor and renal protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.J Cardiovasc Pharmacol. 1994;23:897–906.PubMedCrossRefGoogle Scholar
  31. 31.
    Gluck Z, Reubi FC. Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent.Eur J Clin Pharmacol. 1986;31:107–111.CrossRefPubMedGoogle Scholar
  32. 32.
    Leeman M, van de Borne P, Collart F, et al. Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure.J Cardiovasc Pharmacol. 1993;22:785–791.CrossRefPubMedGoogle Scholar
  33. 33.
    Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.J Am Soc Nephrol. 1998;9:224–230.PubMedGoogle Scholar
  34. 34.
    Aunapuu M, Pechter U, Arend A, Suuroja T, Ots M. Ultrastructural changes in the remnant kidney (after 5/6 nephrectomy) glomerulus after losartan and atenolol treatment.Medicina (Kaunas). 2003;39:975–979.Google Scholar
  35. 35.
    Loutzenhiser R, Griffin K, Williamson G, Bidani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms.Am J Physiol Regul Integr Comp Physiol. 2006;290:R1153-R1167.PubMedGoogle Scholar
  36. 36.
    Kvam FI, Ofstad J, Iversen BM. Effects of antihypertensive drug on autoregulation of RBF and glomerular capillary pressure in SHR.Am J Physiol. 1998;275:F576-F584.PubMedGoogle Scholar
  37. 37.
    Iversen BM, Sekse I, Ofstad J. Resetting of renal blood flow autoregulation in spontaneously hypertensive rats.Am J Physiol. 1987;252:F480-F486.PubMedGoogle Scholar
  38. 38.
    Iversen BM, Kvam FI, Matre K, Ofstad J. Resetting of renal blood autoregulation during acute blood pressure reduction in hypertensive rats.Am J Physiol Renal Physiol. 1998;275:576–584.Google Scholar
  39. 39.
    Willenheimer R, van Veldhuisen DJ, Silke B, et al, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS III).Circulation. 2005;112:2426–2435.CrossRefPubMedGoogle Scholar

Copyright information

© Health Communications Inc 2007

Authors and Affiliations

  • Salvatore Paterna
    • 1
  • Gaspare Parrinello
    • 2
  • Pietro Di Pasquale
    • 3
  • Daniele Torres
    • 2
  • Gabriella La Rocca
    • 1
  • Roberta Antona
    • 1
  • Laura Vernuccio
    • 1
  • Ersilia Fornaciari
    • 1
  • Antonina Tarantino
    • 1
  • Ercole Piccione
    • 1
  • Sergio Fasullo
    • 3
  • Giuseppe Licata
    • 1
  1. 1.Department of Emergency CareUniversity of PalermoItaly
  2. 2.Department of Internal MedicineUniversity of PalermoItaly
  3. 3.Department of CardiologyGF Ingrassia HospitalItaly

Personalised recommendations